PMID- 36982622
OWN - NLM
STAT- MEDLINE
DCOM- 20230330
LR  - 20231103
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 6
DP  - 2023 Mar 14
TI  - Antibody Assay and Anti-Inflammatory Function Evaluation of Therapeutic Potential 
      of Different Intravenous Immunoglobulins for Alzheimer's Disease.
LID - 10.3390/ijms24065549 [doi]
LID - 5549
AB  - Alzheimer's disease (AD) is a common neurodegenerative disease that currently has 
      no known cure. Intravenous immunoglobulin (IVIG), which contains AD-related 
      antibodies and has anti-inflammatory properties, has shown potential as a 
      treatment for AD. However, the efficacy of clinical trials involving AD patients 
      treated with IVIG has been inconsistent. Our previous study found that different 
      IVIGs had significantly varied therapeutic effects on 3xTg-AD mice. In order to 
      investigate the relationship between the composition and function of IVIG and its 
      efficacy in treating AD, we selected three IVIGs that showed notable differences 
      in therapeutic effects. Then, the concentrations of specific antibodies against 
      beta-amyloid (Abeta)(42), tau, and hyperphosphorylated tau (p-tau) in three IVIGs, as 
      well as their effects on systemic inflammation induced by lipopolysaccharide 
      (LPS) in Balb/c mice, were analyzed and compared in this study. The results 
      indicated that these IVIGs differed greatly in anti-Abeta(42)/tau antibody 
      concentration and anti-p-tau ratio, and improved LPS-stimulated peripheral 
      inflammation, liver and kidney injury, and neuroinflammation in Balb/c mice to 
      varying degrees. Combined with our previous results, the efficacy of IVIG against 
      AD may be positively correlated with its level of AD-related antibodies and 
      anti-inflammatory ability. AD-related antibody analysis and functional evaluation 
      of IVIG should be given sufficient attention before clinical trials, as this may 
      greatly affect the therapeutic effect of AD treatment.
FAU - Fei, Zhangcheng
AU  - Fei Z
AUID- ORCID: 0000-0002-3261-7385
AD  - Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Chengdu 610052, China.
FAU - Pei, Renjun
AU  - Pei R
AD  - Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Chengdu 610052, China.
FAU - Pan, Bo
AU  - Pan B
AD  - Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Chengdu 610052, China.
FAU - Ye, Shengliang
AU  - Ye S
AD  - Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Chengdu 610052, China.
FAU - Zhang, Rong
AU  - Zhang R
AD  - Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Chengdu 610052, China.
FAU - Ma, Li
AU  - Ma L
AD  - Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Chengdu 610052, China.
FAU - Wang, Zongkui
AU  - Wang Z
AUID- ORCID: 0000-0002-5764-7660
AD  - Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Chengdu 610052, China.
FAU - Li, Changqing
AU  - Li C
AD  - Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Chengdu 610052, China.
FAU - Du, Xi
AU  - Du X
AD  - Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Chengdu 610052, China.
FAU - Cao, Haijun
AU  - Cao H
AD  - Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Chengdu 610052, China.
LA  - eng
PT  - Journal Article
DEP - 20230314
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Antibodies)
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (tau Proteins)
SB  - IM
MH  - Mice
MH  - Animals
MH  - *Alzheimer Disease/therapy
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - *Neurodegenerative Diseases/drug therapy
MH  - Lipopolysaccharides
MH  - Antibodies/therapeutic use
MH  - Amyloid beta-Peptides
MH  - Anti-Inflammatory Agents/pharmacology/therapeutic use
MH  - Inflammation/drug therapy
MH  - tau Proteins
MH  - Mice, Transgenic
PMC - PMC10058273
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - inflammation
OT  - intravenous immunoglobulin
OT  - tau
OT  - beta-amyloid
COIS- The authors declare no conflict of interest.
EDAT- 2023/03/30 06:00
MHDA- 2023/03/30 06:11
PMCR- 2023/03/14
CRDT- 2023/03/29 01:38
PHST- 2023/02/20 00:00 [received]
PHST- 2023/03/09 00:00 [revised]
PHST- 2023/03/12 00:00 [accepted]
PHST- 2023/03/30 06:11 [medline]
PHST- 2023/03/29 01:38 [entrez]
PHST- 2023/03/30 06:00 [pubmed]
PHST- 2023/03/14 00:00 [pmc-release]
AID - ijms24065549 [pii]
AID - ijms-24-05549 [pii]
AID - 10.3390/ijms24065549 [doi]
PST - epublish
SO  - Int J Mol Sci. 2023 Mar 14;24(6):5549. doi: 10.3390/ijms24065549.